Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

Cancer

Volumn 77, Issue 7, 1996, Pages 1303-1310

  Clemente, Claudio G ^a   Mihm Jr , Martin C ^b   Bufalino, Rosaria ^a   Zurrida, Stefano ^a   Collini, Paola ^a   Cascinelli, Natale ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

melanoma; prognosis; survival; TIL; tumor infiltrating lymphocytes; vertical growth phase

Indexed keywords

ARTICLE; CANCER GROWTH; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS INDEX; MITOSIS RATE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CELL DIVISION; EVALUATION STUDIES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0029925375     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5     Document Type: Article

References (16)

1. Cook MG. The significance of inflammation and regression in melanoma. Virchows Arch A Pathol Anat 1992; 420:113-5.
2. Elder DE, Guerry D IV, Van Horn M, Hurwitz S, Zehngebot L, Goldman LI, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985; 56:413-8.
3. Clark WH Jr, Elder DE, Guerry DP IV, Braitmen LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
4. Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986:; 17:443-50.
5. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978; 144:871-3.
6. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-8.
7. van der Esch EP, Cascinelli N, Preda F, Morabito A, Bufalino R. Stage I melanoma of the skin: evaluation of prognosis according to histologie characteristics. Cancer 1981; 48: 1668-73.
8. Kang S, Serri F, Sober AJ. Regressing melanoma and depigmentation. In: Cascinelli N, Santinami M, Veronesi U, editors. Cutaneous melanomas: biology and management. Milan: Masson, 1990;159-66.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-81.
10. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48.
11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: part I - Introduction and design. Br J Cancer 1976; 34:585-612.
12. Peto R, Pike MC Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: pan II - Analysis and examples. Br J Cancer 1977; 35:1-39.
13. Cox DR. Regression models and life tables (with discussion). J R Star Soc B 1972; 34:187-220.
14. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. Tumor infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1993; 29A:69-75.
15. Balch CM, Riley LB, Bao YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990; 125:200-5.
16. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, et al. Prognostic significance of HER-2/NEU expression in breast cancer and its relationship to other prognostic factors. InI J Cancer 1991;49:44-9.